CD38 and systemic lupus erythematosus: In another study, treating SLE patients with Ruplizumab eliminated their circulating CD38+ plasma cells and reduced their levels of anti-double stranded DNA, proteinuria, and Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) [92].